Consideraciones sobre la asociación de la ateroesclerosis y la artritis reumatoide

Lilian Marivel Caspi Pilamunga; Jorge Andrés Peralvo Saltos; María Fernanda Peralvo Saltos; Sabrina Paola Peralvo Saltos

Consideraciones sobre la asociación de la ateroesclerosis y la artritis reumatoide

Lilian Marivel Caspi Pilamunga, Jorge Andrés Peralvo Saltos, María Fernanda Peralvo Saltos, Sabrina Paola Peralvo Saltos

Texto completo:

PDF

Resumen

La artritis reumatoide y la aterosclerosis son dos enfermedades inflamatorias estrictamente relacionadas. Este trabajo tiene el propósito de mostrar consideraciones de diferentes autores sobre la asociación entre la aterosclerosis y la artritis reumatoide. La inflamación relacionada con la artritis reumatoide puede conducir a la aparición de aterosclerosis de varias maneras. Es importante evaluar y monitorear a los pacientes con artritis reumatoide para detectar la existencia de factores de riesgo tradicionales para la aparición de enfermedad cardiovascular, a fin de reducir el impacto en el sistema cardiovascular.

Palabras clave

ateroesclerosis; artritis reumatoide; asociación entre ateroesclerosis y artritis reumatoide

Referencias

Solomon DH., Karlson EW., Rimm EB., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-1307.

Edwards CJ., Syddall H., Goswami R., et al. Rheumatoid factor may be an Independent risk factor for ischaemic heart disease. Heart. 2007.

Meune C., Touzé E., Trinquart L., Allanore Y. “High risk of clinical cardiovascular évents in rheumatoid arthritis: lévéls of associations of myocardial infarction and stroke through a systématic review and méta-analysis,” Archives of Cardiovascular Diseases, 2010, 103(4):253-261.

Mirjafari H., Al-Husain A., Bruce I. N., “Cardiovascular risk factors in inflammatory arthritis,” Current Opinion in Lipidology, 2011, 22(4):296-301.

Roman MJ., Naqvi TZ., Gardin JM., et al. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr2006;19:943-954.

Chambless LE., Heiss G., Folsom AR., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-494.

Kallbérg H., Ding B., Padyukov L. ét al., “Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks aíter various exposures to cigaréttésmoké,” Annals ofthe Rheumatic Diseases, 2011; 70(3):508-511.

Pemberton P. W., Ahmad Y., Bodill H. ét al., “Biomarkers of oxidant stress, insulin sensitivity and éndothélial activation in rheumatoid arthritis: a cross-sectional study of their associ- ation with accelerated atherosclerosis,” BMC Research Notes, 2009, 2(83).

Goodson N. J., Symmons D. P., Scott D. G., Bunn D., Lunt M, Silman A. J., “Basélinélévéls of C-reactive protein and prediction of déath from cardiovascular disease in patients with inflammatory polyarthritis: a tén-year followup study of a primary care-based inception cohort,” Arthritis and Rheumatism. 2005, 52(8):2293-2299.

Ku I. A., Imboden J. B., Hsué P. Y., Ganz P., “Rheuma- toid arthritis—a modél of systémic inflammation driving athérosclérosis,” Circulation Journal. 2009,73(6):977¬985.

Tanimoto N., Kumon Y., Suéhiro T. ét al., “Serum paraoxonasé activity décreases in rheumatoid arthritis,” Life Sciences. 2003, 72(25):2877-2885.

Marder W., Khalatbari S., Myles J. D. et al., “Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis,” Annals oftheRheumaticDiseases. 2011, 70(9):1550-1555,

Yiu K. H., Wang S., Mok M. Y. et al., “Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification,” Journal of Rheumatology. 2010, 37(3):529-535.

Ahmed H. M. M. S., Youssef M., Mosaad Y. M., “Anti- bodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis,” Clinical Rheumatology. 2010, 29(11):1237-1243.

Pansuria M., Xi H., Li L., Yang X. F., Wang H., “Insulin resistance, metabolic stress, and atherosclerosis,” Frontiers in Bioscience. 2012, 4:916-931.

Bresalier R. S., Sandler R. S., Quan H. et al., “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” The New England Journal of Medicine. 2005, 352(11):1092-1102.

Alacqua M., Trifiro G., Cavagna L. et al., “Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal,” Arthritis Care and Research. 2008, 59(4):568-574.

Van Der Linden M. W., Van Der Bij S., Welsing P., Kuipers E. J., Herings R. M. C., “The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs,” Annals of the Rheumatic Diseases. 2009, 68(5):668-673.

Morrison E., Capell H. A. “Corticosteroids in the management of early and established rheumatoid disease,” Rheumatology. 2006, 45(9):1058-1061.

Makinen H., Kautiainen H., Hannonen P. et al., “Sustained remission and reduced radiographic progression with com- bination disease modifying antirheumatic drugs in early rheumatoid arthritis,” Journal of Rheumatology. 2007, 34(2):316-321.

Landewe R. B. M., Van Den Borne B. E. E. M., Breedveld F. C., Dijkmans B. A. C. “Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity,” The Lancet. 2000, 355(9215):1616-1617.

Tabit C. E., Holbrook M., Shenouda S. M. et al. “Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease,” Vascular Medicine. 2012, 17(2):101-107.

Szekanecz Z., Kerekes G., Soltesz P. “Vascular effects of biologic agents in RA and spondyloarthropathies,” Nature Reviews Rheumatology, 2009, 5(12):677-684.

Da'ien C. I., Duny Y., Barnetche T., Daures J.P, Combe B., Morel J. “Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis,” Annals of the Rheumatic Diseases. 2012, 71(6):862-868.

Gonzalez M. A., Gonzalez C., Vazquez T. R., Miranda J. A., Llorca J. “Insulin resistance in rheumatoid arthritis: the impact of the anti- TNF-a therapy: annals of the New York Academy of Sciences,” Annals of the New York Academy of Sciences. 2010, 1193:153-159.

Gonzalez M. A., Garcia M. T., Gonzalez C., et al. “Anti-TNF-a therapy modulates resistin in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology. 2008, 26(2):311-316.

Hurlimann D., Forster A., Noll G., et al. “Anti-tumor necrosis factor a treatment improves endothelial function in patients with rheumatoid arthritis,” Circulation. 2002, 106(17):2184-2187.

Atzeni F., Turiel M., Caporali R. et al. “The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases,” Autoimmunity Reviews. 2010, 9(12):835-839.

Sarzi-Puttini P., Atzeni F., Shoenfeld Y., Ferraccioli G. “TNF-a, rheumatoid arthritis, and heart failure: a rheumatological dilemma,” Autoimmunity Reviews. 2005, 4(3):53-161.

Kerekes G., Soltesz P., Der H., et al. “Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis” Clinical Rheumatology. 2009, 28(6):705-710.

Enlaces refback

No hay ningún enlace refback.

Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.